BridgeBio Pharma Inc
BBIO47.590USD
+0.220+0.46%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
9.03BCap. mercado
PérdidaP/E TTM
Más Datos de BridgeBio Pharma Inc Compañía
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Información de la empresa
Símbolo de cotizaciónBBIO
Nombre de la empresaBridgeBio Pharma Inc
Fecha de salida a bolsaJun 27, 2019
Director ejecutivoDr. Neil Kumar, Ph.D.
Número de empleados725
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 27
Dirección3160 Porter Dr.
CiudadPALO ALTO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94304
Teléfono16503919740
Sitio Webhttps://bridgebio.com/
Símbolo de cotizaciónBBIO
Fecha de salida a bolsaJun 27, 2019
Director ejecutivoDr. Neil Kumar, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.16M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
1.22M
-1.09%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Europe Middle East and Africa (EMEA)
77.09M
66.10%
United States
36.86M
31.60%
Asia Pacific (APAC)
2.68M
2.30%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Accionistas
Accionistas
Proporción
Viking Global Investors LP
9.80%
The Vanguard Group, Inc.
8.68%
Kohlberg Kravis Roberts & Co. L.P.
6.98%
BlackRock Institutional Trust Company, N.A.
5.89%
Janus Henderson Investors
3.78%
Other
64.87%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
32.61%
Investment Advisor/Hedge Fund
31.42%
Hedge Fund
15.71%
Private Equity
8.99%
Individual Investor
4.95%
Research Firm
3.23%
Venture Capital
1.89%
Sovereign Wealth Fund
0.56%
Bank and Trust
0.49%
Other
0.16%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
620
190.27M
100.20%
-5.13M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
2023Q1
513
164.96M
102.84%
-5.53M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Viking Global Investors LP
18.56M
9.77%
-3.50M
-15.87%
Jun 27, 2025
The Vanguard Group, Inc.
14.87M
7.83%
-177.77K
-1.18%
Mar 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.98%
-6.00M
-31.15%
May 12, 2025
BlackRock Institutional Trust Company, N.A.
11.18M
5.89%
-318.26K
-2.77%
Mar 31, 2025
Janus Henderson Investors
7.17M
3.78%
+2.26M
+46.13%
Mar 31, 2025
Kumar (Neil)
6.16M
3.25%
+5.69K
+0.09%
May 19, 2025
Aisling Capital Management LP
6.07M
3.2%
--
--
Mar 31, 2025
State Street Global Advisors (US)
5.75M
3.03%
-433.01K
-7.00%
Mar 31, 2025
Farallon Capital Management, L.L.C.
5.73M
3.02%
+1.54M
+36.62%
Mar 31, 2025
Capital Research Global Investors
4.67M
2.46%
+1.14M
+32.34%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Tema Oncology ETF
4.11%
Tema Heart & Health ETF
3.19%
Franklin Genomic Advancements ETF
2.39%
SPDR S&P Biotech ETF
2.15%
Virtus LifeSci Biotech Products ETF
2.1%
Direxion Daily S&P Biotech Bull 3X Shares
1.23%
Invesco Nasdaq Biotechnology ETF
0.91%
ProShares Ultra Nasdaq Biotechnology
0.91%
First Trust Mid Cap Growth AlphaDEX Fund
0.83%
iShares Health Innovation Active ETF
0.8%
Ver más
Tema Oncology ETF
Proporción4.11%
Tema Heart & Health ETF
Proporción3.19%
Franklin Genomic Advancements ETF
Proporción2.39%
SPDR S&P Biotech ETF
Proporción2.15%
Virtus LifeSci Biotech Products ETF
Proporción2.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.23%
Invesco Nasdaq Biotechnology ETF
Proporción0.91%
ProShares Ultra Nasdaq Biotechnology
Proporción0.91%
First Trust Mid Cap Growth AlphaDEX Fund
Proporción0.83%
iShares Health Innovation Active ETF
Proporción0.8%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
